CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1632803
This article is part of the Research TopicMolecular Pathways and Signaling Molecules in Cancer Therapy: Advances and InnovationsView all 7 articles
Golidocitinib was used for the first time to treat refractory NK-Large Granular Lymphocytic Leukemia with a STAT3 mutation, accompanied by hemolytic anemia：A Case Report
Provisionally accepted
- Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: NK-large granular lymphocytic leukemia (NK-LGLL) is a rare clonal lymphoproliferative disease of natural killer (NK) cells. In refractory cases, traditional chemotherapy regimens and immunosuppressive drugs often prove ineffective. Hematopoietic stem cell transplantation (HSCT) offers the opportunity to rebuild the immune system, but carries significant risks, including graft-versus-host disease (GVHD). Consequently, alternative therapeutic strategies need to be investigated. A recent study published in The Lancet reported on the use of golidocitinib in the treatment of relapsed or peripheral T-cell lymphoma. Notably, this represents the first clinical report demonstrating the efficacy of golidocitinib in managing intractable NK-large granular lymphocytic leukemia. Case presentation: In this study, we present a case of a 53-year-old male with NK-LGLL who achieved successful therapeutic outcomes with golidocitinib administration. The patient had a documented history of chronic gastritis and was admitted with symptoms of fatigue and chest tightness. Despite receiving various treatments such as methotrexate, cyclosporin, cyclophosphamide, and thalidomide, the patient exhibited treatment refractoriness. However, after initiating treatment with golidocitinib, the patient's blood count improved remarkedly after a single treatment cycle, obviating the need for blood transfusions. The patient maintained golidocitinib treatment without experiencing any serious complications. This is the first reported case demonstrating the efficacy of golidocitinib therapy in treating NK-LGLL. Conclusion: This case highlights the clinical relevance of golidocitinib in developing novel therapeutic strategies for NK-LGLL. Moreover, this treatment option presents the potential as either a bridging therapy or alternative to allo-HSCT.
Keywords: golidocitinib, NK-large granular lymphocytic leukemia, refractory Granular Lymphocytic Leukemia, STAT3 mutation, hemolytic anemia
Received: 21 May 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Hao, Yuan, Zhang and Jian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chen Zhang, Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.